Acronis Introduces Advanced Automation to Simplify MSP Business Operations for Enhanced Productivity
New cloud-centric platform, purpose-built for small and midsize MSPs, improves customer billing, reduces complexity, and maximizes revenues
SCHAFFHAUSEN, Switzerland, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Acronis, a global leader in cyber protection, today announced the general availability of Acronis Advanced Automation. Building on Acronis’ proven track record of delivering integrated solutions that help partners streamline and simplify their services, Acronis Advanced Automation helps MSPs transition from simple break-fix services to cloud-centric, subscription-based services that require a new approach to billing and contract management.
Complexity is a common challenge for MSPs, driven by the numerous business initiatives focused on innovating their products, delivery models, and value-added services. Acronis Advanced Automation is a solution for small and midsize MSPs worldwide who want to simplify and streamline their business operations. With centralized control and management of services, complete time tracking and staff utilization capabilities, and automated, consumption-based billing, Acronis empowers MSPs to gain full visibility of their contracts, delivery, tickets, and work items — maximizing revenue and improving client trust.
"New use cases for native automation solutions continue to emerge in the IT industry and Acronis offers a product that allows MSPs around the world to automate their operations and make better, data-driven decisions. Whether emerging as a startup or evolving to maturity, Acronis Advanced Automation helps service providers control and grow their managed service business", said Patrick Pulvermueller, CEO at Acronis. "We're excited to continue bringing new, innovative automation tools to our Cyber Protect Cloud solution and help MSPs expand their businesses."
Advanced Automation offers MSPs robust capabilities to fuel business growth, including error-free invoices and billing, an integrated service desk, automated time tracking, and support for subscription-based services. These capabilities enable:
- Increased efficiency: Advanced Automation helps MSPs streamline workflows, automate repetitive tasks, and reduce manual effort, allowing for a greater focus on high-value activities.
- Reduced friction in business operations: Advanced Automation simplifies support for subscription-based services.
- Improved productivity: Advanced Automation provides a single platform for managing customer data, tickets, projects, and billing, so MSPs can save time and effort to ultimately deliver faster, more effective services.
- Enhanced customer and employee satisfaction: Advanced Automation helps MSPs better manage customer interactions, and improve communication and responsiveness, leading to an increase in customer satisfaction.
- Greater profitability: Advanced Automation automates processes and reduces manual efforts, which allows MSPs to improve their operational efficiency and profitability.
“Acronis Advanced Automation has automated our invoicing process. We love how it ties in with QuickBooks and makes transferring invoices and data so easy,” said Alex Presman, President at Racom Business. “Automating these time-consuming billing processes allows our team to spend more time on important business procedures like engaging clients and building value-based relationships.”
Acronis Advanced Automation is available for existing Acronis MSP partners, and also those starting a new MSP business. Interested in implementing the solution? For more information, visit: https://www.acronis.com/en-eu/products/cloud/cyber-protect/automation/
Acronis unifies data protection and cybersecurity to deliver integrated, automated cyber protection that solves the safety, accessibility, privacy, authenticity, and security (SAPAS) challenges of the modern digital world. With flexible deployment models that fit the demands of service providers and IT professionals, Acronis provides superior cyber protection for data, applications, and systems with innovative next-generation antivirus, backup, disaster recovery, and endpoint protection management solutions powered by AI. With advanced anti-malware powered by cutting-edge machine intelligence and blockchain based data authentication technologies, Acronis protects any environment - from cloud to hybrid to on premises - at a low and predictable cost.
Acronis is a Swiss company, founded in Singapore. Celebrating two decades of innovation, Acronis has more than 2,000 employees in 45 locations. Acronis Cyber Protect solution is available in 26 languages in over 150 countries and is used by 18,000 service providers to protect over 750,000 businesses.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0a4deba1-b452-40d9-bb21-aa2bdbb284cfTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20234.12.2023 22:30:00 CET | Press release
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2023 96,431,770 Total gross of voting rights: 96,431,770 Total net* of voting rights: 96,186,256 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.4.12.2023 22:16:59 CET | Press release
Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025 PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces today the closing of the previously announced subscription by Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”) for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (“ADSs”), for an aggregate amount of $4.8 million, equivalent to €4.6 million1 (the “Remaining Placement Amount”, and the subscription transaction being the “Remaining Placement”), following the approval by the French Ministry of Economy of JJ
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH4.12.2023 22:05:00 CET | Press release
The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety dataThe safety assessment was based on the review of safety data from more than 500 patients, including patients that have been treated with lanifibranor for more than 72 weeksThe DMC review remains consistent, confirming the good safety profile of lanifibranor Daix (France), Long Island City (New York, United States), December 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the positive recommendation from the third meeting of the Data Monitoring Committee (DMC) to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH without modification to the trial protocol. The DMC
Standard Lithium to Participate in December Investor Conferences4.12.2023 22:04:35 CET | Press release
VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced its participation in the following virtual December investor conferences: Event:Deustche Bank 8th Annual Virtual Lithium Battery Supply Chain ConferenceDate:December 6, 2023Panel:US Based Lithium Supply, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:15am PTEvent:Bank of America Securities Virtual 2023 Lithium and Battery Storage ConferenceDate:December 7, 2023Panel:Company Presentation, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:30am PT Management will be hosting one-on-one meetings during the conferences. Interested investors should contact their Deutsche Bank or Bank of America representative or Standard Lithium Investor Relations at email@example.com. About Standard Lithium Ltd. St
Resignation of Director4.12.2023 20:00:33 CET | Press release
December 4, 2023 Announcement no. 19 Resignation of Director COPENHAGEN, DENMARK and BOSTON, MA, USA, December 4, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) announced today that Jan Leth Christensen has informed the Company that he has decided to resign from his position as a board member for BioPorto. The search for a successor with relevant expertise, including familiarity with public company practices in the Nordics, will be initiated and a new candidate is expected to be proposed in connection with the Company’s Annual General Meeting in 2024. “Jan has served on the board since the Annual General Meeting held in 2021. I would like to thank Jan for his important contributions to the board and collaboration in general” said John McDonough, BioPorto’s Chaiman of the Board of Directors. For investor inquiries, please contact: HC Andersen Capital, EU Investor Relations, +45 4529 0000, firstname.lastname@example.org Ashley R. Robinson, US Investor Relations,